Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clinical Genetics and Genomics, |
RCV001269546 | SCV001449604 | pathogenic | not provided | 2015-12-15 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003770408 | SCV004659067 | likely pathogenic | ALG3-congenital disorder of glycosylation | 2023-10-09 | criteria provided, single submitter | clinical testing | This sequence change affects the initiator methionine of the ALG3 mRNA. The next in-frame methionine is located at codon 75. This variant is present in population databases (no rsID available, gnomAD 0.001%). Disruption of the initiator codon has been observed in individual(s) with congenital disorders of glycosylation type I (PMID: 27172925). ClinVar contains an entry for this variant (Variation ID: 988293). This variant disrupts a region of the ALG3 protein in which other variant(s) (p.Pro39Leu) have been observed in individuals with ALG3-related conditions (PMID: 18679822). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |